2026 Fundraising Snapshot
A R R AY  B I O P H A R M A’ S 
I N F LU E N C E  A N D 
I M PAC T  
Three companies with 
notable 2026 transactions 
were founded by 
former leaders of Array 
BioPharma. At a recent 
Innosphere: Innovation 
After Hours Life Sciences 
event in Boulder, former 
Array cofounders and 
leaders Kevin Koch, Ph.D., 
Tony Piscopio, Ph.D., and 
Kyle Lefkoff reflected on 
the company’s lasting 
impact. They shared 
how Array BioPharma’s 
leadership and approach 
to drug development 
influenced a new 
generation of companies 
and shaped nearly 1,000 
Colorado life sciences 
professionals.
“We collected the 
greatest set of drug 
hunters in biotech 
history,” said Lefkoff. 
The group also pointed 
to the next generation of 
companies built by Array 
BioPharma leaders and 
scientists, including 
Edgewise Therapeutics, 
OnKure, OrbiMed, 
ArcherDx, BoCo Bio, and 
Ambrosia Biosciences.
Think Bioscience
Series A biotechnology company developing small 
molecule drugs for historically challenging drug targets.
Spun out from the University of Colorado Boulder, 
which ranked #1 in the nation for startups launched 
from university research in 2025, more than Stanford 
and MIT.
CBSA RECOGNITION
2022: Colorado BioScience Association Rising Star 
of the Year Finalist
2022, 2024: Rocky Mountain Life Sciences Investor 
& Partnering Conference Presenting Company
OnKure Therapeutics
Clinical-stage biopharma company developing novel 
precision medicines to selectively target specific 
mutations shown to be key drivers of cancer and 
other diseases.
Launched by a successful biotech executive with 
ties to Array BioPharma, OnKure raised a $7M Seed 
Round in 2018 and enrolled its first patient in phase 1 
clinical trials the following year.
CBSA RECOGNITION
2019: Rocky Mountain Life Sciences Investor 
& Partnering Conference Presenting Company
2021: Colorado BioScience Association Company 
of the Year Finalist
Edgewise Therapeutics
Commercial-stage biotech with a clinical pipeline 
of therapies for serious muscle diseases with 
life-limiting impact.
Founded by serial entrepreneurs from Array 
BioPharma, which was acquired by Pfizer in 2019 for 
$11.8B, the largest acquisition of a venture-backed life 
sciences company in the history of Colorado.
CBSA RECOGNITION
2021: Colorado BioScience Association Deal of the 
Year Winner
2024: Colorado BioScience Association Company 
of the Year Winner
Ambrosia Biosciences
Series B drug discovery company developing orally 
delivered, small molecule-based therapies for obesity 
and other metabolic disorders.
In 2024, an entrepreneur in residence at Boulder 
Ventures and an Array BioPharma cofounder saw the 
opportunity to accelerate company formation, hiring 
25 leading drug hunters when Pfizer exited Colorado.
CBSA RECOGNITION
2024: Rocky Mountain Life Sciences Investor 
& Partnering Conference Presenting Company
2025: Colorado BioScience Association Rising Star 
of the Year Winner
$55M
S E R I E S  A
$150M
PRIVATE PLACEMENT
$2.65B
SALE OF BUSINESS
$100M
S E R I E S  B
2026-27 BIOSCIENCE COLORADO     15

View this content as a flipbook by clicking here.